Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | ITGB3 | P05106 | 14/20 | 0.45 |
| ▸ | ITGA2B | P08514 | 14/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | F2R | P25116 | 5/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2745501 | 0.88 | LMNA (0.50) | LMNAITGB3ITGA2BALDH1A1MAPK1 | |
| SCHEMBL2744881 | 0.84 | LMNA (0.47) | LMNACYP3A4 | |
| SCHEMBL2747483 | 0.81 | ITGB3 (0.47) | LMNAITGB3ITGA2BALDH1A1MAPK1 | |
| SCHEMBL5542690 | 0.80 | ITGB3 (0.49) | LMNAITGB3ITGA2BALDH1A1F2R | |
| SCHEMBL2746554 | 0.79 | ALDH1A1 (0.54) | LMNAALDH1A1MAPK1NPC1RAB9A | |
| SCHEMBL2746603 | 0.78 | ITGB3 (0.51) | LMNAITGB3ITGA2BALDH1A1MAPK1 | |
| SCHEMBL13691346 | 0.78 | ITGB3 (0.51) | ITGB3ITGA2BALDH1A1F2RNPC1 | |
| SCHEMBL12966315 | 0.77 | ALDH1A1 (0.57) | ITGB3ITGA2BALDH1A1F2RNPC1 | |
| SCHEMBL12818553 | 0.77 | ALDH1A1 (0.57) | ITGB3ITGA2BALDH1A1F2RNPC1 | |
| SCHEMBL12818111 | 0.77 | ALDH1A1 (0.57) | ITGB3ITGA2BALDH1A1F2RNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8178681-B2 | methyl 3-methyl-2-{[2-oxo-1-(2-oxo-ethyl)-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carbonyl]-amino}-butyrate; cannabinoid receptor agonist; antiinflammatory agent, immunostimulant, analgesic; atopic dermatitis; excellent in photostability, and have excellent transdermal and oral absorbency | SHIONOGI & CO., LTD. (JP) | 2012-05-15 | — | — | US | disclosed |
| US-20080103139-A1 | 3-Carbamoyl-2-Pyridone Derivative | SHIONOGI & CO. LTD. (JP) | 2008-05-01 | — | — | US | disclosed |
| EP-1806342-A1 | 3-CARBAMOYL-2-PYRIDONE DERIVATIVE | SHIONOGI & CO., LTD. (JP) | 2007-07-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080103139-A1 | 3-Carbamoyl-2-Pyridone Derivative | CNR1, CNR2, HRH4 | LMNA 3604/4885ITGB3 2478/4885ITGA2B 4078/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.